| GSK2982772 / GSK |
NCT02302404: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects |
|
|
| Completed | 1 | 79 | Europe | GSK2982772 solution, GSK2982772 capsule, Placebo solution, Placebo capsule | GlaxoSmithKline, Clinical Unit at Cambridge (Addenbrooks) | Inflammatory Bowel Diseases | 03/16 | 03/16 | | |
NCT03590613: Phase I Study of GSK2982772 in Japanese Healthy Male Participants |
|
|
| Completed | 1 | 13 | Japan | GSK2982772, Placebo | GlaxoSmithKline | Autoimmune Diseases | 09/18 | 09/18 | | |
NCT03305419: A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects |
|
|
| Completed | 1 | 62 | Europe | GSK2982772 capsule, Placebo capsule | GlaxoSmithKline | Autoimmune Diseases | 10/18 | 10/18 | | |
NCT03266172: A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses |
|
|
| Completed | 1 | 45 | Europe | GSK2982772 Modified Release, GSK2982772 Immediate Release | GlaxoSmithKline, Quotient Clinical | Autoimmune Diseases | 11/18 | 11/18 | | |
NCT03649412: A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 |
|
|
| Completed | 1 | 33 | Europe | GSK2982772 Modified Release, GSK2982772 Immediate Release | GlaxoSmithKline, Quotient Sciences | Autoimmune Diseases | 05/19 | 05/19 | | |
NCT04316585: A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants |
|
|
| Completed | 1 | 29 | Europe, Canada | GSK2982772, Placebo | GlaxoSmithKline | Psoriasis | 09/21 | 10/21 | | |
|
